Question Bank › The knock on the company is going stale

The knock on the company is going stale

The knock on the company is going stale: this quarter's own facts cut against the standing doubt

Calls Tested
287
Answered YES
68
Hit Rate
23.7%
rare by design

Inogen, Inc. (INGN) — this company's answers

NO on the Q1 2023 call 2023-05-05 F
The model's full reasoning — Q1 2023 call → NO我们根据提供的财报电话会议记录,分析是否存在一个明确的、公司特定的疑虑,以及本季度的实际运营证据是否反驳了该疑虑。 首先,寻找疑虑。电话会议中,管理层多次提到“回归盈利”、“调整后EBITDA转正”等目标。分析师的问题也围绕增长、B2B波动、DTC生产力等。但最突出的疑虑似乎是公司能否实现盈利,以及增长是否可持续。管理层在开场就强调“回归盈利”和“调整后EBITDA在第四季度转正”。分析师Mike Matson问及第二季度收入,管理层只给出年度指引,暗示增长压力。分析师还问及B2B波动和DTC生产力。但更具体的疑虑可能是:公司能否摆脱亏损?管理层在回答中提到了“我们仍然专注于回归盈利,并预计在2023年第四季度实现调整后EBITDA为正”。这暗示投资者担心亏损持续。 然而,本季度的实际证据:管理层报告了收入符合预期,毛利率和EBITDA优于内部预期。DTC生产力提高(每代表单位数和收入均实现两位数增长),租赁收入增长25.4%,国内B2B增长146.7%(但基数低)。国际B2B下降,DTC下降。但管理层强调供应充足,且正在改善。关键的是,管理层说“我们继续看到对我们产品的潜在需求,并看到了可扩展和盈利增长的路径”。但这是否是实际证据?本季度净亏损仍为2030万美元,调整后EBITDA为负1180万美元。所以亏损仍在继续,但管理层说“优于内部预期”。然而,疑虑是能否盈利,而本季度仍然亏损,只是亏损幅度可能好于预期。但管理层说“我们预计在第四季度实现正调整后EBITDA”,这是预测,不是本季度事实。本季度实际证据是亏损,但管理层说“毛利率和EBITDA表现优于内部预期”,这暗示亏损收窄?但数字上,调整后EBITDA为负1180万,去年同期呢?没有给出去年同期调整后EBITDA,但总亏损为2030万,去年同期净亏损?从电话中,去年Q1净亏损?没有直接数据,但管理层说“总运营费用增加”,但收入下降。所以本季度亏损可能扩大?实际上,收入下降10.2%,运营费用增加,所以亏损可能扩大。但管理层说“毛利率和EBITDA表现优于内部预期”,可能指相对于内部预算,但实际仍是亏损。 疑虑是否明确?分析师问及“增长”和“B2B波动”,但更核心的疑虑可能是公司能否实现盈利。管理层在开场就强调“回归盈利”,这暗示投资者担心。但本季度实际证据是亏损,虽然管理层说优于预期,但并未扭亏。所以本季度证据并未反驳疑虑,反而可能确认疑虑(亏损持续)。但管理层说“我们预计第四季度转正”,这是未来计划。 另一个可能的疑虑:DTC业务下滑,但管理层说生产力提高,但实际DTC收入下降29.2%。所以疑虑可能是DTC能否恢复增长?但本季度DTC收入下降,虽然生产力提高,但总体下降。所以证据并未反驳。 再考虑B2B波动,但本季度国内B2B增长146%,但基数低,且管理层说“软启动”,所以可能波动。 最明显的疑虑可能是“公司能否实现盈利”,因为管理层反复强调“回归盈利”和“调整后EBITDA转正”。但本季度仍然亏损,所以证据并未反驳,反而可能支持疑虑。但管理层说“毛利率和EBITDA表现优于内部预期”,这暗示亏损幅度小于预期,但仍是亏损。所以没有明确反驳。 另一个疑虑:供应问题?管理层说供应改善,但本季度收入下降,但管理层说不是供应问题。所以供应疑虑被反驳?但供应疑虑是过去的,现在说供应充足,但本季度收入下降,所以可能需求问题。 我认为没有明确的、公司特定的疑虑被本季度实际证据反驳。管理层主要用未来计划回应,而不是本季度事实。例如,关于盈利,管理层说“我们预计第四季度转正”,这是预测。关于DTC,管理层说“生产力提高”,但收入下降。所以证据并未明确反驳。 因此,答案应为NO。

← Back to the full INGN analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: Reading this call as a whole, can you identify ONE well-defined DOUBT that has clearly been weighing on how this company is perceived — a standing knock evident from the transcript itself, such as skepticism that its losses will ever end, that its main product or model will find repeat demand, that its legacy business's decline will swamp everything else, that it depends too heavily on one customer, market, or financing source, or another comparable company-specific concern — AND does the CURRENT PERIOD'S OWN OPERATING EVIDENCE, as recounted by management, move clearly AGAINST that doubt? Answer YES when BOTH halves come through in the transcript, in whatever form fits the business: (1) A STANDING, COMPANY-SPECIFIC DOUBT IS VISIBLE ON THE CALL. The transcript itself shows that a particular concern has hung over this company — through analysts returning to it, management acknowledging what skeptics or investors have worried about, or management plainly addressing a question it knows the audience carries (can this business make money, will anyone buy this at scale, will the decline stop, can they fund themselves, will the big customer stay). The doubt must be specific to this company's situation, not generic macro gloom, and must read as something that predates this quarter rather than arising on this call. (2) THIS PERIOD'S REAL ACTIVITY CUTS AGAINST IT. Management recounts concrete things that actually happened in the recent period — actual orders, customers returning or expanding, real revenue or volumes where there had been little, losses narrowing because of how the business itself is now running, the doubted product performing in real use, the feared departure or decline not occurring while something better did — described with enough operating substance that the contradiction rests on observed events rather than on reassurance, plans, or projections. The evidence need not fully settle the doubt; what matters is that the current period's facts point the other way and management engages the doubt with those facts. Answer NO if no company-specific doubt is discernible — an ordinarily healthy company reporting a routine quarter. NO if the doubt exists but management answers it mainly with confidence, vision, targets, or hoped-for improvements rather than with things that already happened. NO if the period's evidence actually confirms the doubt (the losses widened, the decline continued, the customer left) and management is excusing it. NO if the contrary evidence is a one-time item, an asset sale, a financing, or something management itself treats as non-recurring rather than the business operating differently. NO if the doubt and the evidence never connect — strong facts reported on one topic while the standing concern sits elsewhere untouched. NO if the doubt appears only as boilerplate risk language or an analyst aside that management never engages. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
CRGO Freightos Limited Q1 2024 2024-05-20 C+
IFS Intercorp Financial Services Inc. Q1 2024 2024-05-14 C+
PRA ProAssurance Corporation Q1 2024 2024-05-11 D
LTRX Lantronix, Inc. Q3 2024 2024-04-29 C
ASB Associated Banc-Corp Q1 2024 2024-04-25 A
GL Globe Life Inc. Q1 2024 2024-04-23 F
ASM Avino Silver & Gold Mines Ltd. Q4 2023 2024-03-21 C+
KOPN Kopin Corporation Q4 2023 2024-03-14 C+
GIII G-III Apparel Group, Ltd. Q4 2024 2024-03-14 C
HP Helmerich & Payne, Inc. Q1 2024 2024-01-30 C
PFE Pfizer Inc. Q4 2023 2024-01-30 F
QTRX Quanterix Corporation Q3 2023 2023-11-07 B
ALL The Allstate Corporation Q3 2023 2023-11-02 C+
DASH DoorDash, Inc. Q3 2023 2023-11-01 C+
PTN Palatin Technologies, Inc. Q4 2023 2023-09-29 D
BZUN Baozun Inc. Q2 2023 2023-08-28 D
GVP GSE Systems, Inc. Q1 2023 2023-05-15 D
BXSL Blackstone Secured Lending Fund Q1 2023 2023-05-10 A
FTHM Fathom Holdings, Inc. Q1 2023 2023-05-10 C
SPIR Spire Global, Inc. Q1 2023 2023-05-10 B
SBRA Sabra Health Care REIT, Inc. Q1 2023 2023-05-04 B
BRX Brixmor Property Group Inc. Q1 2023 2023-05-02 A
TACT TransAct Technologies Incorporated Q4 2022 2023-03-08 A
VRE Veris Residential, Inc. Q4 2022 2023-02-22 D
TOST Toast, Inc. Q4 2022 2023-02-16 C+
PKOH Park-Ohio Holdings Corp. Q3 2022 2022-11-13 B
CLSD Clearside Biomedical, Inc. Q3 2022 2022-11-09 C
SIBN SI-BONE, Inc. Q3 2022 2022-11-07 C+
CHE Chemed Corporation Q3 2022 2022-11-01 B+
YMM Full Truck Alliance Co. Ltd. Q2 2022 2022-08-25 C+
EXFY Expensify, Inc. Q2 2022 2022-08-12 D
WD Walker & Dunlop, Inc. Q2 2022 2022-08-09 C+
DM Desktop Metal, Inc. Q2 2022 2022-08-08 F
XHR Xenia Hotels & Resorts, Inc. Q2 2022 2022-08-05 A
LIN Linde plc Q2 2022 2022-07-28 B+
CME CME Group Inc. Q2 2022 2022-07-27 B
OGI OrganiGram Holdings Inc. Q3 2022 2022-07-14 B+
SE Sea Limited Q1 2022 2022-05-17 F
VNRX VolitionRx Limited Q1 2022 2022-05-12 F
OPK OPKO Health, Inc. Q1 2022 2022-05-09 D
FARM Farmer Bros. Co. Q3 2022 2022-05-07 D
BFIN BankFinancial Corporation Q1 2022 2022-05-06 A
BXP Boston Properties, Inc. Q1 2022 2022-05-03 A
STC Stewart Information Services Corporation Q1 2022 2022-04-29 C+
LOW Lowe's Companies, Inc. Q3 2021 2021-11-17 B+
CYBR CyberArk Software Ltd. Q3 2021 2021-11-04 B+
IPGP IPG Photonics Corporation Q3 2021 2021-11-02 C
SXC SunCoke Energy, Inc. Q3 2021 2021-11-01 A
EMR Emerson Electric Co. Q3 2021 2021-08-04 B+
EEX Emerald Holding, Inc. Q2 2021 2021-08-01 C+
GECC Great Elm Capital Corporation Q3 2018 2018-11-13 B
UMH UMH Properties, Inc. Q3 2018 2018-11-02 C+
FOSL Fossil Group, Inc. Q1 2018 2018-05-08 C
BCOV Brightcove Inc. Q1 2018 2018-04-26 B+
AVT Avnet, Inc. Q2 2018 2018-01-25 B
PII Polaris Inc. Q3 2017 2017-10-24 C+
GNTX Gentex Corporation Q3 2017 2017-10-20 B
MTG MGIC Investment Corporation Q3 2017 2017-10-18 B+
LIND Lindblad Expeditions Holdings, Inc. Q2 2017 2017-08-06 C
BIIB Biogen Inc. Q2 2017 2017-07-25 B
CAG Conagra Brands, Inc. Q2 2017 2016-12-22 C+
WYY WidePoint Corporation Q3 2016 2016-11-09 D
ULBI Ultralife Corporation Q3 2016 2016-10-29 C+
ARAY Accuray Incorporated Q4 2016 2016-08-17 B
GES Guess?, Inc. Q1 2017 2016-05-25 F
RCL Royal Caribbean Cruises Ltd. Q1 2016 2016-04-29 C+
DD DuPont de Nemours, Inc. Q1 2016 2016-04-26 B+
HPP Hudson Pacific Properties, Inc. Q4 2015 2016-02-25 C

How the model reasoned

BRX · Q1 2023 → YESThe question asks if there's a standing company-specific doubt visible on the call, and if this period's operating evidence cuts against it. YES The standing doubt is the skepticism that tenant disruptions (especially bankruptcies like Bed Bath) will create occupancy pressure and throw markets out of equilibrium, given the recaptured space and potential for more filings. This is visible in analyst questions (Todd Thomas on Bed Bath impact and market equilibrium; others circling back on bad debt 75-110 bps and bankruptcy activity) and management's acknowledgment that "recent retailer bankruptcy announcements will result in occupancy pressure" while noting they've "been preparing for the last several quarters." This period's evidence cuts against it: record 94% total occupancy (up sequentially in a seasonally weak quarter), small-shop at 89.
CME · Q2 2022 → YESThe question is: Identify ONE well-defined DOUBT that has been weighing on the company, and see if the current period's operating evidence moves against that doubt. YES The standing doubt is the perceived risk that the legacy NEX Group businesses (BrokerTec and EBS) would continue to show range-bound revenue and fail to deliver meaningful growth despite a constructive macro backdrop, as directly raised by Alex Blostein. Management engages this concern head-on by recounting concrete operating evidence from 2Q: BrokerTec US treasuries ADV up 14% YoY, US repo up 25% YoY, EU repo up 14% YoY, plus $4.5 billion in new cross-sell volume from previously non-trading clients and record RV trading volumes of $2.4 billion; 90% of the migration to Globex is complete, with the remaining EBS migration also finished and system enhancements underway.
BXSL · Q1 2023 → YESThe question asks if there's a standing company-specific doubt visible in the transcript, and if this period's operating evidence moves against it. YES The standing doubt visible in the transcript is the skepticism that BXSL’s credit performance will be materially worse than the broader private-credit market because of its exposure to higher-rate environments and the “tails” of the portfolio (i.e., the small slice of companies whose interest-coverage ratios could fall below 1× when 5 % rates are stress-tested). Management itself flags this concern by noting that “it is less about averages… much more about the tails” and that investors keep asking about the percentage of the portfolio below 1× ICR. This quarter’s operating evidence directly counters that doubt: - 0.

More from the question bank

Acted like it's already biggerBetting on a claim they haven't proven yetMoney already collected for work not yet donNew faces on the callThe streak is aliveCommitted past the numbersAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.